DEEPVESSEL Plaque

by Keya Medical Technology Co., Ltd.  · Based in China → — FDA-cleared AI-powered CCTA analysis to quantify plaque burden, characterize plaque, and assess coronary stenosis.
Cardiology Cardiothoracic Surgery Radiology

Regulatory Status Disclosed

Overview

DEEPVESSEL Plaque by Keya Medical Technology Co., Ltd. is an AI-powered medical tool designed for the analysis of coronary computed tomography angiography (CCTA) studies.

  • What it does:The tool characterizes and quantifies coronary atherosclerotic plaque and stenosis from previously acquired CCTA images. It provides quantitative measurements including total plaque volume, calcified and non-calcified plaque volume, low-density plaque volume, plaque burden, and stenosis severity, along with CAD-RADS stenosis categorization.
  • Who it is for:DEEPVESSEL Plaque is intended for qualified clinicians to assess the presence and extent of coronary artery disease (CAD) in adults with suspected or known CAD. This includes specialties such as cardiology and radiology, and it can be utilized in care settings where CCTA studies are performed and interpreted.
  • How it fits a clinical or practice workflow:The workflow involves secure transfer of previously acquired CCTA DICOM data. Deep-learning-based segmentation is then performed and reviewed by trained analysts. Finally, quantitative and visual clinical reports are delivered for review by the clinician.
  • Notable capabilities:DEEPVESSEL Plaque offers detailed vessel- and patient-level plaque volumes, burden, composition, and stenosis assessment through visual clinical reports.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered coronary plaque analysis
  • Quantifies plaque burden
  • Characterizes plaque composition (calcified, non-calcified, low-density)
  • Assesses coronary stenosis
  • Provides quantitative plaque measurements
  • Generates visual clinical reports
  • Segments coronary arteries, vessel walls, and lumen structures
  • Supports clinical decision-making for coronary artery disease (CAD)
  • Compatible with previously acquired CCTA studies
  • Integration with DEEPVESSEL FFR for comprehensive cardiac analysis

Use Cases

  • Assessing the presence and extent of coronary atherosclerosis
  • Evaluating coronary artery disease (CAD) in adults with suspected or known CAD
  • Supporting clinical decision-making for patient management strategies
  • Complementing expert CCTA interpretation with standardized, scalable AI-assisted plaque assessment

What Physicians Need to Know

Cardiac CT/MRI Analysis
DEEPVESSEL Plaque is an FDA-cleared AI-powered software that analyzes previously acquired Coronary Computed Tomography Angiography (CCTA) data. It provides quantitative plaque measurements, characterizes plaque, and assesses stenosis.
Coronary Artery Assessment
The tool helps clinicians assess the presence and extent of coronary atherosclerosis by providing quantitative plaque measurements, stenosis categorization, and visual clinical reports. It quantifies total plaque volume, non-calcified plaque volume, calcified plaque volume, low-density plaque volume, and plaque burden.
AHA/ACC Guideline Alignment
While DEEPVESSEL Plaque itself is not explicitly stated to be aligned with AHA/ACC guidelines in the provided information, the broader context of quantitative coronary plaque analysis from CCTA is supported by recent ACC/AHA scientific statements. These statements highlight the prognostic value of quantifying coronary plaque and reinforce the role of CCTA in CAD patient management.
Physician Tip

DEEPVESSEL Plaque offers a comprehensive anatomical assessment of coronary artery disease. Combining its quantitative plaque analysis and stenosis evaluation with DEEPVESSEL FFR (a separate, complementary tool for functional assessment) can provide a more complete picture from a single CCTA examination, aiding in more precise risk stratification and personalized treatment planning. The detailed reports, including plaque volumes, burden, composition, and stenosis assessment, can be valuable for monitoring disease progression and guiding therapeutic interventions.

DEEPVESSEL Plaque processes previously acquired CCTA DICOM data through a secure remote workflow. It is designed to complement DEEPVESSEL FFR, with both being separately FDA-cleared products that can be used together for a more comprehensive CCTA assessment.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentCloud-based
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Cardiology, Cardiothoracic Surgery, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DEEPVESSEL Plaque

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for DEEPVESSEL Plaque.

View all on YouTube

Frequently Asked Questions

DEEPVESSEL Plaque is an FDA-cleared, AI-powered software that analyzes coronary CT angiography (CCTA) images to characterize and quantify coronary atherosclerotic plaque and stenosis. It provides quantitative plaque measurements and visual reports, helping clinicians assess the presence and extent of coronary artery disease (CAD) and support clinical decision-making.
DEEPVESSEL Plaque provides detailed quantitative measurements including total plaque volume, calcified and non-calcified plaque volume, low-density plaque volume, plaque burden, and stenosis severity. It also offers CAD-RADS stenosis categorization and visual clinical reports.
Yes, DEEPVESSEL Plaque is FDA-cleared. It received 510(k) clearance (K260497) on June 4, 2026, as automated radiological image-processing software under 21 CFR 892.2050 (product code QIH).
DEEPVESSEL Plaque is designed to analyze previously acquired CCTA studies, integrating into existing imaging workflows by providing quantitative data and visual reports for clinical review. However, it's important to note that the software processes already-acquired images and provides quantified output, rather than controlling image acquisition or rendering an autonomous diagnosis; the diagnostic responsibility remains with the clinician. High-quality CCTA images are required for accurate analysis, and plaque brightness can vary based on technical factors.
While DEEPVESSEL Plaque offers AI-powered quantitative plaque analysis, traditional methods involve manual evaluation of CCTA images, which can be time-consuming and less precise for quantifying plaque volumes. Other AI-powered solutions for cardiac CT analysis are emerging, focusing on similar goals of enhancing plaque detection and risk assessment.
Specific pricing for DEEPVESSEL Plaque is not publicly detailed, but Keya Medical, the developer, mentions 'patient- and payer-centric pricing' for its DEEPVESSEL FFR product, which is a complementary tool. For non-invasive FFR estimates derived from CCTA software analysis, a new Category I CPT code (75580) was implemented starting January 1, 2024, which may impact reimbursement for such AI-assisted analyses.
DEEPVESSEL Plaque and DEEPVESSEL FFR are complementary, separately FDA-cleared products from Keya Medical. DEEPVESSEL Plaque focuses on anatomical assessment by quantifying plaque and stenosis from CCTA. DEEPVESSEL FFR, on the other hand, is deep-learning-based software that calculates CT-derived fractional flow reserve (FFR) values from CCTA data to evaluate the functional significance of coronary artery disease.

Related Tools

Exo Iris
Exo Imaging, Inc.
Cardiology AI
PanEcho
Yale School of Medicine (Cardiovascular Data Science Lab)
Cardiology AI
PanEcho is an AI tool from Yale School of Medicine that interprets echocardiograms with high accuracy, performing 39 diagnostic tasks and detecting conditions like severe aortic stenosis and systolic dysfunction.
Hexoskin Medical
Hexoskin
Cardiology AI
EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.

See all Cardiology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-09-23 | First Added: 2026-09-23
AI Tool Finder
AI-powered search. Results may not be comprehensive.